Physician profile
Rajiv Kumar
NPI 1689681173
$31,207.73
in general payments reported to CMS, 2019-2025
38 companies · $4,769 in 2025
The $4,769 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,007 · 2020: $3,389 · 2021: $5,372 · 2022: $5,271 · 2023: $4,653 · 2024: $4,746 · 2025: $4,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,168.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,589.24 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $2,241.10 | 2019-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Tris Pharma INC | $2,203.45 | 2019-2025 | Dyanavel Xr, Onyda Xr, Quillichew Er |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,997.78 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,488.67 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $1,420.69 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,378.78 | 2019-2025 | Trintellix |
| Allergan, INC. | $1,272.50 | 2019-2020 | |
| Lundbeck LLC | $1,053.44 | 2019-2025 | Rexulti |
| Harmony Biosciences LLC | $1,028.12 | 2020-2025 | Wakix |
| Avanir Pharmaceuticals, INC. | $894.02 | 2019-2022 | |
| Alkermes, INC. | $883.05 | 2022-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $681.31 | 2019-2023 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $657.64 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $572.02 | 2022-2025 | Auvelity, Sunosi |
Show all 37 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.